Improvement of lower urinary tract dysfunction by a monoacylglycerol lipase inhibitor in mice with spinal cord injury
Neurourology and Urodynamics · 2024
DOI: 10.1002/nau.25458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurourology and Urodynamics, 2024. Verfasst von Kang Jun Cho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Monoacylglycerol Lipases, Spinal Cord Injuries, Mice, Inbred C57BL, Urinary Bladder. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
Aims
Activation of the endocannabinoid system by monoacylglycerol lipase (MAGL) blockade may affect the lower urinary tract function. We investigated the effect of an MAGL inhibitor, MJN110, on neurogenic lower urinary tract dysfunction (LUTD) in the mouse model of spinal cord injury (SCI).
Methods
Female C57BL/6 mice that underwent spinal cord transection at T8–10 level were divided into three groups consisting of (1) vehicle‐treated SCI mice, (2) 5 mg/kg, or (3) 10 mg/kg of MJN110‐treated SCI mice. MJN110 and vehicle were administered intraperitoneally for 7 days from 4 weeks after spinal cord transection. We then conducted awake cystometrograms and compared urodynamic parameters between three groups. The expression of cannabinoid (CB) receptors, TRP receptors, and inflammatory cytokines in L6‐S1 dorsal root ganglia (DRG) or the bladder mucosa were evaluated and compared among three groups. Changes in the level of serum 2‐arachidonoylglycerol (2‐AG) and bladder MAGL were also evaluated.
Results
In the cystometrogram, detrusor overactivity (DO) parameters, such as the number of nonvoiding contraction (NVC), a ratio of time to the 1st NVC to intercontraction interval (ICI), and NVC integrals were improved by MJN110 treatment, and some effects were dose dependent. Although MJN110 did not improve voiding efficiency, it decreased bladder capacity, ICI, and residual urine volume compared to vehicle injection. MJN110 treatment groups had lower CB2, TRPV1, TRPA1, and inflammatory cytokines mRNA levels in DRG and bladder mucosa. Serum 2‐AG was increased, and bladder MAGL was decreased after MAGL inhibitor treatment.
Conclusions
MAGL inhibition improved LUTD including attenuation of DO after SCI. Thus, MAGL can be a therapeutic target for neurogenic LUTD after SCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Urology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Urology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
- Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Förderung
- NIDDK NIH HHS
- NIH HHS
Zitieren
APA
Cho, K. J., Hashimoto, M., Karnup, S., Matsuoka, K., Kamijo, T., Kim, J. C., Koh, J. S., & Yoshimura, N. (2024). Improvement of lower urinary tract dysfunction by a monoacylglycerol lipase inhibitor in mice with spinal cord injury. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25458
Vancouver
Cho KJ, Hashimoto M, Karnup S, Matsuoka K, Kamijo T, Kim JC, et al. Improvement of lower urinary tract dysfunction by a monoacylglycerol lipase inhibitor in mice with spinal cord injury. Neurourology and Urodynamics. 2024. doi:10.1002/nau.25458
BibTeX
@article{Cho2024,
author = {Cho, Kang Jun and Hashimoto, Mamoru and Karnup, Sergei and Matsuoka, Kanako and Kamijo, Tadanobu and Kim, Joon Chul and Koh, Jun Sung and Yoshimura, Naoki},
title = {Improvement of lower urinary tract dysfunction by a monoacylglycerol lipase inhibitor in mice with spinal cord injury},
journal = {Neurourology and Urodynamics},
year = {2024},
doi = {10.1002/nau.25458}
}
EUVIMED